Evidence map›Paper›PMID 40777946›Full record

ArticleAfrican health sciences2024

Diversity and antibiotic sensitivity of uropathogens from a regional hospital in Rwanda.

Charles O Odongo, Jean Baptiste Niyibizi, Ezechiel Bizimana, Irènèe Nshimiyimana, Deogratias Ruhangaza

Abstract read
In one paragraph

Article in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles O OdongoDivision of Basic Medical Sciences, School of Medicine, University of Global Health Equity, P.O.Box 6955, Kigali-Butaro, Rwanda.
Jean Baptiste NiyibiziDivision of Basic Medical Sciences, School of Medicine, University of Global Health Equity, P.O.Box 6955, Kigali-Butaro, Rwanda.
Ezechiel BizimanaDivision of Basic Medical Sciences, School of Medicine, University of Global Health Equity, P.O.Box 6955, Kigali-Butaro, Rwanda.
Irènèe NshimiyimanaDivision of Basic Medical Sciences, School of Medicine, University of Global Health Equity, P.O.Box 6955, Kigali-Butaro, Rwanda.
Deogratias RuhangazaDivision of Basic Medical Sciences, School of Medicine, University of Global Health Equity, P.O.Box 6955, Kigali-Butaro, Rwanda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Urinary tract infections are a common cause for antibiotic consumption. Empirical treatment is common for community-acquired infections owing to predictability of pathogens. Objectives: Describe sensitivity profiles of uropathogens at a regional hospital in Rwanda. Methods: Hospital-based cross-sectional study in which clean-catch urine samples were analyzed. A two-stage process involving dipstick urinalysis and urine culture was used to identify true infections. The Kirby-Bauer disc diffusion method was used for antibiotic sensitivity analysis as per EUCAST guidelines. Results: Of 198 samples studied, 107 met criterion for UTI with 94 yielding significant growth. Klebsiella pneumoniae (35%), and Escherichia coli (32%) were the most common organisms isolated. Others included Staphylococcal species, Proteus spp, Enterobacter spp and Salmonella. Very high resistance frequencies (above 70%) were observed against amoxycillin, cotrimoxazole, trimethoprim, aztreonam and fosfomycin. Resistance to fluoroquinolones, aminoglycosides and cephalosporins varied between 40-60%. High levels of cross resistance were observed for drugs of the same class. Resistance to the potentiated penicillins, meropenem, cefoxitin and nitrofurantoin were less than 30%. Piperacillintazo bactum performed best with 91% sensitivity against all organisms tested. Conclusion: High levels of resistance were observed for most antibiotics studied. For empirical treatment of community-acquired UTI in our setting, nitrofurantoin remains effective while ciprofloxacin is not.

Indexed as

Anti-Bacterial AgentsBacteriaUrinary Tract InfectionsAdolescentAdultAgedCross-Sectional StudiesDrug Resistance, BacterialEscherichia coliFemaleHumansKlebsiella pneumoniaeMaleMicrobial Sensitivity TestsMiddle AgedRwandaAnti-Bacterial AgentsDiversity and antibiotic sensitivityRwandauropathogens

Identifiers

PMID40777946
PMCPMC12327148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.